Revolution Medicines, Inc. (RVMD)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Net unrealized gain (loss) on marketable securities | - | 5,675 | ||
| Comprehensive income (loss), net of tax, attributable to parent | - | -150,613 | ||
| Research and development | 224,134 | 151,752 | ||
| General and administrative | 40,580 | 23,960 | ||
| Total operating expenses | 264,714 | 175,712 | ||
| Loss from operations | -264,714 | -175,712 | ||
| Other nonoperating income (expense), total | - | 282 | ||
| Interest income | 22,404 | 20,411 | ||
| Interest and other income (expense), net | -899 | - | ||
| Change in fair value of warrant liabilities and contingent earn-out shares | -4,578 | -1,269 | ||
| Total other income, net | 16,927 | 19,424 | ||
| Loss before income taxes | -247,787 | -156,288 | ||
| Net loss | -247,787 | -150,613 | ||
| Net loss per share attributable to common stockholders, basic | -1.31 | -0.94 | ||
| Net loss per share attributable to common stockholders, diluted | -1.31 | -0.94 | ||
| Weighted average number of shares outstanding, diluted | 188,583,288 | 166,843,984 | ||
| Weighted-average shares used to compute net loss per share attributable to common stockholders-basic | 188,583,288 | 166,843,984 | ||